Search Results 61-70 of 9610 for Tuberculous lymphadenitis
The purpose of this study is to evaluate Lamprene (Clofazimine) to treat non-tuberculous mycobacterial (NTM) infections. ... tuberculous mycobacterium lung ...
Risk factors and outcomes of non-tuberculous mycobacteria infection in lung transplant recipients: A systematic review and meta-analysis. J Heart Lung ...
Mayo Clinic's role in developing the first effective tuberculosis treatment. Patricia Thomas was trying to keep up her spirits. Her cough was not improving.
Mayo Clinic has been working to end TB ever since the first clinical trials were conducted by its physicians back in the first half of the 20th century.
Also, infectious disease specialist Dr. Stacey Rizza has an update on tuberculosis. March 24 is World TB Day. And, pathologist Dr. Bobbi Pritt has the latest on ...
... tuberculosis, and is difficult to treat. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...
Lymphadenopathy. Merck Manual Professional Version. https://www ... Lymphangitis and lymphadenitis. In: Current Medical Diagnosis & Treatment ...
Jacksonville, Fla. The purpose of this study is to evaluate Lamprene (Clofazimine) to treat non-tuberculous mycobacterial (NTM) infections. Molecular Analysis ...
Jacksonville, Fla. The purpose of this study is to evaluate Lamprene (Clofazimine) to treat non-tuberculous mycobacterial (NTM) infections. A Study ...
The purpose of this study is to evaluate Lamprene (Clofazimine) to treat non-tuberculous mycobacterial (NTM) infections. A Study to Evaluate the QuantiFERON-TB ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.